Supplemental material
Journal of Medical Economics
Volume 24, 2021 - Issue 1
Oncology
Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a MET exon 14 skipping mutation in the United States
Beilei Caia Novartis Pharmaceuticals Corporation, East Hanover, NJ, USACorrespondence[email protected]
https://orcid.org/0000-0002-2762-3908
https://orcid.org/0000-0002-2762-3908, Zheng-Yi Zhoub Analysis Group, Inc., Boston, MA, USAhttps://orcid.org/0000-0001-9014-8479
https://orcid.org/0000-0001-9014-8479, Weiguang Xueb Analysis Group, Inc., Boston, MA, USAhttps://orcid.org/0000-0003-0713-2869
https://orcid.org/0000-0003-0713-2869, Nisha C. Hazrab Analysis Group, Inc., Boston, MA, USAhttps://orcid.org/0000-0002-1424-6525
https://orcid.org/0000-0002-1424-6525, , , Diana Brixnerd Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USAhttps://orcid.org/0000-0001-6637-6359
https://orcid.org/0000-0001-6637-6359, Gary Oderdad Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USAhttps://orcid.org/0000-0001-9664-0296
https://orcid.org/0000-0001-9664-0296 & Joseph Biskupiakd Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USAhttps://orcid.org/0000-0002-9436-0984
https://orcid.org/0000-0002-9436-0984 show all